JAK2 and MPL mutations in myelodysplastic syndromes and mixed myelodysplastic/myeloproliferative neoplasms.
| Authors . | Proportion of cases that were found to be positive forJAK2(V617F) . | MPLmutations . |
|---|---|---|
| Abbreviations: CMML, chronic myelomonocytic leukemia; ET, essential thrombocythemia; MDS/MPD, U, myelodysplastic/myeloproliferative disease, unclassifiable; RARS-T, refractory anemia with ringed sideroblasts associated with marked thrombocytosis | ||
| Szpurka et al29 | 6/9 RARS-T 3/26 MDS/MPD, U 2/22 CMML | Not studied |
| Remacha et al30 | 6/9 RARS-T | Not studied |
| Wang et al31 | 6/12 RARS-T with plt count ≥ 600 × 109/L 0/19 RARS-T with plt count < 600 × 109/L 0/11 MDS/MPD, U | Not studied |
| Boissinot et al32 | 5/16 RARS-T (5/8 RARS-T with ET features) | Not studied |
| Ceesay et al33 | 4/6 RARS-T | Not studied |
| Renneville et al34 | 5/7 RARS-T | Not studied |
| 2/15 CMML | ||
| Gattermann et al35 | 9/10 RARS-T | Not studied |
| Schnittger et al36 | — | MPL (W515) mutation in a case with features of both ET and RARS-T |
| Schmitt-Graeff et al37 | 11/23 RARS-T | MPL (W515) mutation in 1 JAK2 (V617F)-negative patient with RARS-T |
| Raya et al38 | 14/23 (61%) RARS-T with plt count ≥ 600 × 109/L 3/24 RARS-T with plt count 400–600 × 109/L (all had plt count > 500 × 109/L | Not studied |
| Ingram et al39 | 6/97 MDS with del(5q) | Not studied |
| Authors . | Proportion of cases that were found to be positive forJAK2(V617F) . | MPLmutations . |
|---|---|---|
| Abbreviations: CMML, chronic myelomonocytic leukemia; ET, essential thrombocythemia; MDS/MPD, U, myelodysplastic/myeloproliferative disease, unclassifiable; RARS-T, refractory anemia with ringed sideroblasts associated with marked thrombocytosis | ||
| Szpurka et al29 | 6/9 RARS-T 3/26 MDS/MPD, U 2/22 CMML | Not studied |
| Remacha et al30 | 6/9 RARS-T | Not studied |
| Wang et al31 | 6/12 RARS-T with plt count ≥ 600 × 109/L 0/19 RARS-T with plt count < 600 × 109/L 0/11 MDS/MPD, U | Not studied |
| Boissinot et al32 | 5/16 RARS-T (5/8 RARS-T with ET features) | Not studied |
| Ceesay et al33 | 4/6 RARS-T | Not studied |
| Renneville et al34 | 5/7 RARS-T | Not studied |
| 2/15 CMML | ||
| Gattermann et al35 | 9/10 RARS-T | Not studied |
| Schnittger et al36 | — | MPL (W515) mutation in a case with features of both ET and RARS-T |
| Schmitt-Graeff et al37 | 11/23 RARS-T | MPL (W515) mutation in 1 JAK2 (V617F)-negative patient with RARS-T |
| Raya et al38 | 14/23 (61%) RARS-T with plt count ≥ 600 × 109/L 3/24 RARS-T with plt count 400–600 × 109/L (all had plt count > 500 × 109/L | Not studied |
| Ingram et al39 | 6/97 MDS with del(5q) | Not studied |